Cadrenal Therapeutics, Inc. Common Stock (CVKD)

USD 12.96

(13.19%)

Market Cap (In USD)

21.49 Million

Revenue (In USD)

-

Net Income (In USD)

-8.35 Million

Avg. Volume

27.47 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.4-32.55
PE
-
EPS
-
Beta Value
0.0
ISIN
US1276361086
CUSIP
CIK
1937993
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Quang X. Pham
Employee Count
-
Website
https://www.cadrenal.com
Ipo Date
2023-01-20
Details
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

More Stocks